Education
About Us
Working with TipRanks
Follow Us
Proteonomix (PROT)
:PROT
PROT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume4.60K
Average Volume (3M)0.00
Market Cap
$8.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta6.74
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,911,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PROT FAQ
What was Proteonomix ’s price range in the past 12 months?
Proteonomix lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Proteonomix ’s market cap?
Proteonomix ’s market cap is $8.00.
When is Proteonomix ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Proteonomix ’s earnings last quarter?
Currently, no data Available
Is Proteonomix overvalued?
According to Wall Street analysts Proteonomix ’s price is currently Overvalued.
Does Proteonomix pay dividends?
Proteonomix does not currently pay dividends.
What is Proteonomix ’s EPS estimate?
Proteonomix ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteonomix have?
Proteonomix has 7,911,000 shares outstanding.
What happened to Proteonomix ’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Proteonomix ?
Currently, no hedge funds are holding shares in PROT
Company Description
Proteonomix
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Hepion Pharmaceuticals
―
Windtree Therapeutics
―
Universe Pharmaceuticals
―